FRA
NBIX icon

Front Row Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Front Row Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-66
Closed -$9.09K – 726
2024
Q2 		$9.09K Sell
66
-10
-13% -$1.37K ﹤0.01% 606
2024
Q1 		$10.5K Buy
+76
New +$10.4K ﹤0.01% 575
2023
Q4 		– Sell
-65
Closed -$7.31K – 693
2023
Q3 		$7.31K Sell
65
-1
-2% -$105 ﹤0.01% 589
2023
Q2 		$6K Hold
66
– – ﹤0.01% 640
2023
Q1 		$7K Sell
66
-1
-1% -$104 ﹤0.01% 605
2022
Q4 		$8K Buy
67
+6
+10% +$703 ﹤0.01% 549
2022
Q3 		$7K Sell
61
-16
-21% -$1.62K ﹤0.01% 578
2022
Q2 		$8K Buy
77
+8
+12% +$738 ﹤0.01% 558
2022
Q1 		$6K Buy
69
+18
+35% +$1.52K ﹤0.01% 676
2021
Q4 		$4K Hold
51
– – ﹤0.01% 797
2021
Q3 		$5K Hold
51
– – ﹤0.01% 746
2021
Q2 		$5K Hold
51
– – ﹤0.01% 747
2021
Q1 		$5K Sell
51
-6
-11% -$629 ﹤0.01% 736
2020
Q4 		$5K Hold
57
– – ﹤0.01% 693
2020
Q3 		$5K Sell
57
-5
-8% -$578 ﹤0.01% 693
2020
Q2 		$8K Hold
62
– – 0.01% 526
2020
Q1 		$6K Buy
62
+9
+17% +$881 ﹤0.01% 586
2019
Q4 		$6K Hold
53
– – ﹤0.01% 580
2019
Q3 		$5K Buy
53
+13
+33% +$1.22K ﹤0.01% 608
2019
Q2 		$3K Hold
40
– – ﹤0.01% 752
2019
Q1 		$4K Hold
40
– – ﹤0.01% 653
2018
Q4 		$3K Buy
40
+26
+186% +$2.49K ﹤0.01% 696
2018
Q3 		$1 Buy
+14
New +$1.59K ﹤0.01% 916

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Front Row Advisors's NBIX Position: Q3 2024 in Review

Front Row Advisors sold out of Neurocrine Biosciences (NBIX) in Q3 2024, closing a stake of 66 shares — an estimated $9.09K sold.

Front Row Advisors first reported a position in NBIX in Q3 2018 and held it in 23 quarters. The position peaked at $10.5K in Q1 2024. 574 funds tracked by Wall St. Rank hold NBIX as of Q3 2024.

  • Front Row Advisors reported no remaining Neurocrine Biosciences position as of Q3 2024 after selling out during the quarter.
  • Front Row Advisors sold 66 Neurocrine Biosciences shares in Q3 2024, an estimated $9.09K.
  • Front Row Advisors first reported a position in Neurocrine Biosciences in Q3 2018 and held it in 23 quarters.
  • Front Row Advisors's Neurocrine Biosciences position peaked at $10.5K in Q1 2024.
  • 574 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2024.

Based on Front Row Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.